Approval · Notice of Compliance 1492 · 2000
WARX TABLETS: Notice of Compliance 1492
Issued October 5, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1492
- Date
- October 5, 2000
- Company
- Taro Pharmaceuticals IncBrampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Therapeutic class
- Anticoagulant
- Canadian reference product
- COUMADIN (Dupont Pharma Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| WARX TABLETS | 02242881 | — |
| WARX TABLETS | 02242882 | — |
| WARX TABLETS | 02242883 | — |
| WARX TABLETS | 02242884 | — |
| WARX TABLETS | 02242885 | — |
| WARX TABLETS | 02242886 | — |
| WARX TABLETS | 02242887 | — |
| WARX TABLETS | 02242888 | — |
| WARX TABLETS | 02242889 | — |
Medicinal ingredients
- WARFARIN SODIUM 1 MG per TAB
- WARFARIN SODIUM 2 MG per TAB
- WARFARIN SODIUM 2.5 MG per TAB
- WARFARIN SODIUM 3 MG per TAB
- WARFARIN SODIUM 4 MG per TAB
- WARFARIN SODIUM 5 MG per TAB
- WARFARIN SODIUM 6 MG per TAB
- WARFARIN SODIUM 7.5 MG per TAB
- WARFARIN SODIUM 10 MG per TAB